Kevin Outterson, JD, LLM

Kevin Outterson is a research collaborator with PORTAL and the Austin B. Fletcher Professor of Law at Boston University, where he leads the Social Innovation on Drug Resistance program. He is also the founding Executive Director and Principal Investigator of the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership that works to accelerate a diverse portfolio of innovative antibacterial products toward clinical development and regulatory approval.

Outterson’s primary areas of expertise are the law and economics of antimicrobial resistance, particularly push and pull incentives for antimicrobials. He has participated in many major reports and initiatives on antibacterial research and development, and served on the Advisory Panel for the Longitude Prize. He received the 2015 Leadership Award from the Alliance for the Prudent Use of Antibiotics for his research and advocacy work.

Outterson publishes in legal and peer-reviewed medical and health policy journals, including Yale Journal of Health Policy, Law and Ethics; Cardozo Law Review; University of Pittsburgh Law Review; Kansas Law Review; American Journal of Law & Medicine; New England Journal of Medicine; Health Affairs; The Lancet Infectious Diseases; Clinical Infectious Diseases; and the Journal of Law, Medicine & Ethics. Since 2000, he has published more than 90 peer-reviewed and legal articles.

Outterson is past editor-in-chief of the Journal of Law, Medicine & Ethics; current faculty co-advisor to the American Journal of Law & Medicine; past chair of the Section on Law, Medicine & Health Care of the Association of American Law Schools; former director of the health law program; and former President and Board member of the American Society of Law, Medicine & Ethics. Before his academic career, he was a partner at two major US law firms.